# Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

> **NCT01331122** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Chelsea Therapeutics**

## Conditions studied

- Gait Disorders, Neurologic

## Interventions

- **DRUG:** droxidopa

## Key facts

- **NCT ID:** NCT01331122
- **Lead sponsor:** Chelsea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Never initiated. Withdrawn by sponsor.
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331122, "Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01331122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*